Raffort Juliette, Lareyre Fabien, Massalou Damien, Fénichel Patrick, Panaïa-Ferrari Patricia, Chinetti Giulia
Clinical Chemistry Laboratory, University Hospital of Nice, Nice, France.
Université Côte d'Azur, Institute for Research on Cancer and Aging, Nice, France.
Biochem Med (Zagreb). 2017 Jun 15;27(2):308-324. doi: 10.11613/BM.2017.034.
Glicentin is a proglucagon-derived peptide mainly produced in the L-intestinal cells. While the roles of other members of the proglucagon family including glucagon-like peptide 1, glucagon-like peptide 2 and oxyntomodulin has been well studied, the functions and variation of glicentin in human are not fully understood. Experimental and clinical studies have highlighted its role in both intestinal physiology and glucose metabolism, pointing to its potential interest in a wide range of pathological states including gastrointestinal and metabolic disorders. Due to its structure presenting many similarities with the other proglucagon-derived peptides, its measurement is technically challenging. The recent commercialization of specific detection methods has offered new opportunities to go further in the understanding of glicentin physiology. Here we summarize the current knowledge on glicentin biogenesis and physiological roles. In the limelight of clinical studies investigating glicentin variation in human, we discuss future directions for potential applications in clinical practice.
胰高血糖素原衍生肽主要在肠L细胞中产生。虽然胰高血糖素原家族的其他成员，包括胰高血糖素样肽1、胰高血糖素样肽2和胃泌酸调节素的作用已得到充分研究，但人类中胰高血糖素原衍生肽的功能和变异尚未完全了解。实验和临床研究突出了其在肠道生理学和葡萄糖代谢中的作用，表明它在包括胃肠道和代谢紊乱在内的多种病理状态中具有潜在的研究价值。由于其结构与其他胰高血糖素原衍生肽有许多相似之处，其检测在技术上具有挑战性。最近特定检测方法的商业化提供了新的机会，以进一步了解胰高血糖素原衍生肽的生理学。在此，我们总结了目前关于胰高血糖素原衍生肽生物合成和生理作用的知识。在调查人类中胰高血糖素原衍生肽变异的临床研究的关注下，我们讨论了其在临床实践中潜在应用的未来方向。
